Gilead's Harvoni beats Sovaldi, AbbVie's Viekira Pak in hep C drug safety: Advera

Drug safety numbers have been weighing in Gilead's ($GILD) favor lately, with recent analyses showing that its hep C superstars Harvoni and Sovaldi are safer than AbbVie's ($ABBV) rival med Viekira Pak. But Harvoni could be the safest option of the three, turning up the fewest reports of serious side effects, according to a new report by healthcare informatics firm Advera Health Analytics. More from FiercePharma